financial guidance
Abbott Lowers FY21 Guidance as It Sees Sharp Decline in COVID-19 Test Revenue
The firm's CEO said that despite the decline, its base business is returning to normal and has "strong momentum."
DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand
The company said that its Q1 revenue growth was driven in part by SARS-CoV-2 test revenues of €102.0 million, booked mainly in the US, Canada, and Europe.
Castle Biosciences Q1 Revenues Up 31 Percent
The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.
Meridian Bioscience Fiscal Q2 Revenues Up 49 Percent
Despite the overall revenue increase, revenues from Meridian's diagnostic segment were down 9 percent.
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
May 5, 2021
Personalis Q1 Revenues Grow 9 Percent
May 5, 2021
CareDx Q1 Revenues up 76 Percent
May 3, 2021
Qiagen Q1 Revenues Jump 52 Percent
Apr 22, 2021
Danaher Q1 Revenues Up 58 Percent
Apr 21, 2021
Roche Diagnostics Q1 Sales Climb 50 Percent
Apr 5, 2021
Illumina Preliminary Q1 Revenues Grow 26 Percent
Feb 25, 2021
Natera Revenues Grow 35 Percent in Q4
Feb 25, 2021
Berkeley Lights Q4 Revenues Rise 31 Percent
Feb 24, 2021